Full history for every metric is available with a Kvantra account

Stock profile
Illumina, Inc. logo

Illumina, Inc. (ILMN)

Country: United States of AmericaSector: HealthcareIndustry: Medical - Diagnostics & ResearchExchange: NASDAQ
P/E TTM
33.1
History
P/E NTM
31.7
Market cap
29.15B
Currency USD
KvantraRankAbout63
IValue24
IIQuality91
IIIMomentum86
Current price
192.82 USD-3.91%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m3,2394,5264,5844,5044,3724,3384,5384,629
Operating profit$m864960
Net profit$m656762-4,404-1,161-1,223850895839
EPS reported$5.455.82
Operating cashflow per share$6.968.15
Capex per share$0.951.15
FCF per share$6.017.00
Free cash flow$m9311,057
Net debt$m920976
Book value equity$m2,7233,145
Book value per share$17.4620.42
Number of sharesm156154
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx24.7633.13
P/B LTMx7.659.27
P/S LTMx4.816.42
P/FCF LTMx22.3927.58
EV/EBITDA LTMx15.0921.91
EV/Sales LTMx5.066.64
Earnings Yield LTM%4.04%3.02%
FCF Yield%4.47%3.63%
Quality
ROE%31.22%31.45%
ROIC%11.21%14.15%
Operating margin%18.58%21.15%
Gross margin%66.08%67.87%
FCF/Sales%21.44%23.29%
Growth and momentum
EPS Growth YoY%-+30.49%
Sales Growth YoY%-0.78%+5.90%
Net Income Growth YoY%-+27.31%
FCF Growth%+31.31%+5.70%
Operating Profit Growth%-+23.08%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx0.360.46
Net Debt/EBITDAx0.800.74
EBIT/Net interestx7.9919.20
Net debt/market cap%4.41%3.35%
Net debt/Equityx0.340.31
Gross debt/equityx0.940.74

ETFs that hold Illumina

FundTickerPosition#Weight
Vanguard Morningstar Small-Cap ETFVB50.52%
Vanguard Morningstar Small-Cap Growth ETFVBK51.18%
ARK Genomic Revolution ETFARKG94.42%
iShares Nasdaq US Biotechnology UCITS ETFBTEC.L82.03%
Invesco NASDAQ Biotech UCITS ETFSBIO.L82.04%
Invesco Biotechnology & Genome ETFPBE84.67%
WCM Quality Global Growth ETF (Quoted Managed)WCMQ.AX102.59%
EA Series Trust - EA Bridgeway Aggressive Investors ETFBAGX101.55%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE54.88%
Invesco Nasdaq Biotechnology ETFIBBQ82.04%

Funds with Illumina among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price192.82 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Illumina, Inc. (ILMN)

ILMN · NASDAQ · Healthcare
192.82 USD-3.91%
Sign up to track this stock
Benchmarks
KvantraRank63
Market cap29.15B
P/E NTM31.7
P/E TTM33.1
KvantraRank?63 / 100
Value
24
Quality
91
Momentum
86
Financialsin USD
20242025TTM2026E
ETFs that hold Illumina
FundTickerPosition#Weight
Vanguard Morningstar Small-Cap ETFVB50.52%
Vanguard Morningstar Small-Cap Growth ETFVBK51.18%
ARK Genomic Revolution ETFARKG94.42%
iShares Nasdaq US Biotechnology UCITS ETFBTEC.L82.03%
Invesco NASDAQ Biotech UCITS ETFSBIO.L82.04%
Invesco Biotechnology & Genome ETFPBE84.67%
WCM Quality Global Growth ETF (Quoted Managed)WCMQ.AX102.59%
EA Series Trust - EA Bridgeway Aggressive Investors ETFBAGX101.55%
Global X Genomics & Biotechnology UCITS ETFGN0M.DE54.88%
Invesco Nasdaq Biotechnology ETFIBBQ82.04%

Funds with Illumina among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current192.82 USD
Upside
Price consensus
Last year average price target
Current price192.82 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

IndustryMedical - Diagnostics & Research
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free